by Patricia Wilson-Smith | Dec 31, 2025 | Sickle Cell News
Why winter can be harder with SCD Cold exposure can contribute to pain episodes for many people with sickle cell. Winter also adds: school schedule disruptions, respiratory illness spikes, holiday travel, and weather-related access issues. A practical winter checklist...
by Patricia Wilson-Smith | Dec 31, 2025 | Sickle Cell News
In August 2025, Reuters reported that Pfizer’s experimental sickle cell drug inclacumab failed to meet its main goal in a late-stage study (no significant difference in vaso-occlusive crisis frequency vs placebo). Reuters Why this still matters When a trial fails, it...
by Patricia Wilson-Smith | Dec 31, 2025 | Advocacy & Policy, Education, Sickle Cell News
In January 2025, the Oklahoma Health Care Authority published an annual update evaluating how SoonerCare serves members with sickle cell disease—an ongoing effort tied to state legislative requirements. Welcome to Oklahoma’s Official Web Site The key point:...
by Patricia Wilson-Smith | Dec 31, 2025 | Advocacy & Policy, Education, Medicine, Sickle Cell News
In late 2024, Pfizer withdrew voxelotor (Oxbryta) from the market globally after concluding the risks outweighed the benefits. ASH Research Collaborative+1That decision hit patients and clinicians hard—because many people had built their routine around it. New...
by Patricia Wilson-Smith | Dec 31, 2025 | Sickle Cell News
If you’ve been following gene therapy for sickle cell disease (SCD), you’ve probably heard about Casgevy (exa-cel)—a CRISPR-based gene-editing therapy currently approved for some patients ages 12+. In early December 2025, Vertex reported that children ages 5–11 in a...
